ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2020年09月22日 08時50分
Avance Clinical Announces Expanded eClinical Solutions for Biotech Clinical Trials at BioPharm America
オーストラリア・アデレード, 2020年09月22日 - (JCN Newswire) - The leading Australian CRO for biotechs, and Frost & Sullivan 2020 Asia-Pacific CRO Market Leadership Award winner, Avance Clinical has expanded its eClinical solutions offering, with advanced digital clinical tools for enhanced patient engagement, visibility, data capture, and analysis. www.avancecro.com/eclinical-solutions
Avance Clinical made the announcement at BioPharm America (September 21-24, 2020)
Avance Clinical's biotech clients now have the option to deploy the latest eClinical solutions to maximise the value of study data and deliver real-time visibility on study progress.
Avance Clinical CEO Yvonne Lungershausen said:
"Our Data Management team works with eClinical leaders such as Medrio to offer regulatory compliant and patient centric tools for rapid start-up and continual data flow. These tools improve patient engagement and data collection and allow Sponsors to stay informed at every step with Sponsor visible portals."
The Avance Clinical eClinical services include the following:
eSource
- Direct data capture of source data on site
- Forms customised by Avance Clinical Data Management team
- Edit checks built into forms; instant firing of queries once data is entered
- Option for data to be collected off-line and synced when on-line is available
- Fully integrated with Medrio EDC, data visible for Sponsor review instantly
- Remote monitoring and data review on ongoing basis
- Avance Clinical provision of tablets if required
eConsent
- Electronic consent including patient sign-off and investigator confirmation
- Customisable to include animations, videos and questions as required
- Forms customised by Avance Clinical Data Management team
- Link via email to patient
- Compatible with any device and internet system (smart phones, tablet, laptop, desktop)
- Integrated with Medrio EDC
- Link can be shared with HREC as part of submission package
ePRO
- Electronic capture of patient reported outcome, including diary data, dosing compliance, questionnaires, VAS/Pain scales
- Forms customised by Avance Clinical Data Management team
- Link via email to patient
- Options for emails and reminders at set times during the day or week
- Timezone adjusted to patient's location
- Compatible with any device and internet system (smart phones, tablet, laptop, desktop)
- Fully integrated with Medrio EDC, data visible for Sponsor review instantly
Glynn Morrish, Avance Clinical Director Biometrics said:
"Direct electronic capture of study information and the complimentary suite of solutions offered by Avance Clinical allows the company and its clients to maximise clinical trial efficiency and flexibility while ensuring data integrity is preserved. Our highly trained and experienced biometrics team are excited to continue to work at the forefront of innovation and technology and provide services that offer stability and robustness to studies being conducted in an ever-changing global environment."
Avance Clinical is an Australian owned Contract Research Organisation that has been providing high-quality clinical research services fit for global regulatory standards to the local and international drug development industry for 20 years.
Considering Australia? Contact us about your next study.
https://www.avancecro.com/eclinical-solutions/
About Avance Clinical www.avancecro.com
Australia's Avance Clinical has more than 20-years of experience and is now one of Australia's leading Contract Research Organizations.
Avance Clinical is committed to providing high-quality clinical research services with its highly-experienced team. The collective pool of knowledge and experience at Avance Clinical continually grows through the careful selection of experts who also demonstrate passion in their chosen field.
Avance Clinical offers high-quality services in an established clinical trial ecosystem, that includes world-class Investigators and Sites able to access specialized patient groups.
Other benefits include:
1. The Government R&D grant means up to 43.5% rebate on clinical trial spend
2. eClinical solutions - speed and continuity
3. Site Initiation Visit (SIV) and Study Start achieved in 5 - 6 weeks
4. No IND required for clinical trials
5. Full GMP material is not mandated for Phase I clinical trials
6. Established clinical trial environment with world-class Investigators and sites
7. Established healthy subject databases and specialized patient populations
8. Five independent Phase 1 facilities across Australia including hospital-based units for critical care
9. Major hospitals with world-class infrastructures and dedicated Clinical Trial Units with a long track-record in FDA compliant research
10. Seasonal studies: Northern hemisphere Sponsors can conduct their studies year-round by taking advantage of Australia's counter-flu and allergy seasons
Media Contact:
media@avancecro.com
Chris Thompson
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
Hitachi High-Tech Announces the SU9600: Next-Generation Ultrahigh-Resolution Scanning Electron Microscope with High Throughput
Nov 01, 2025 00:45 JST
Sharp to Introduce AQUOS sense10 Smartphone
Nov 01, 2025 00:27 JST
Fujitsu to provide digital ticketing service for NTT DOCOMO's new d ticket platform
Nov 01, 2025 00:07 JST
HTD1801, a First-in-Class Anti-inflammatory Metabolic Modulator, Demonstrates Durable 52-Week Efficacy and Safety in Two Phase III Trials in Type 2 Diabetes Mellitus
Oct 31, 2025 09:30 JST
MHI and Nippon Shokubai to Develop Ammonia Cracking System for NEDO's "Development of Technologies for Building a Competitive Hydrogen Supply Chain" Project
Oct 30, 2025 23:14 JST
NEC and e& Sign MoU to Drive Joint Sustainability Initiatives
Oct 30, 2025 22:46 JST
MHI Thermal Systems Launches Two New Models of Air-to-Water Heat Pumps Using Natural Refrigerant R290 for European Market
Oct 30, 2025 22:19 JST
Hitachi Energy and Blackstone Energy Transition Partners enter strategic partnership to create leading energy service provider in North America
Oct 30, 2025 21:40 JST
MHI-MS to Conduct Demonstration Testing of Vehicle Transport Robots at Nakagusuku Port in Okinawa
Oct 30, 2025 17:58 JST
DENSO Hosted a Press Briefing at JAPAN MOBILITY SHOW 2025
Oct 30, 2025 17:29 JST
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma
Oct 30, 2025 14:43 JST
Mazda Presents World Premiere of Two Vision Models at Japan Mobility Show 2025
Oct 30, 2025 14:33 JST
Mazda Rolls Out New Version of Brand Symbol from Japan Mobility Show 2025
Oct 30, 2025 14:26 JST
NEC and the Cambodian Mine Action Center Successfully Predict Landmine-Contaminated Areas in Cambodia Using AI
Oct 30, 2025 14:18 JST
Overview of Honda CEO Speech at the Japan Mobility Show 2025
Oct 30, 2025 14:00 JST
Honda Presents World Premiere of the Prototype of Honda 0 a, new SUV Model for Honda 0 Series at Japan Mobility Show 2025
Oct 30, 2025 11:55 JST
Honda Presents World Premiere of Super-ONE Prototype Compact EV at Japan Mobility Show 2025
Oct 30, 2025 11:50 JST
Mitsubishi Motors Debuts Mitsubishi Elevance Concept and Adventure-Inspiring Lineup at Japan Mobility Show 2025
Oct 30, 2025 11:39 JST
Fujitsu and PwC Japan partner on economic security measures for sovereign cloud solution
Oct 30, 2025 11:22 JST
Hitachi Rail becomes world's first transportation firm to adopt new NVIDIA IGX Thor solution for real-time AI
Oct 30, 2025 11:00 JST
More Latest Release >>